Okan KURTBOLAT, Halil ASCI, Mehtap SAVRAN, Pınar KARABACAK, Esra Nurlu TEMEL, Ozgür ONAL, Melih ARLIOGLU, Ahmet BINDAL, Orhan IMECI
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi - 2026;33(3):315-325
Objective: This study aims to clarify the possible interactions of Linezolid, a drug used during infection treatment in intensive care units, with other drugs and to provide information to stakeholders in clinical use. Material and Method: Data from the files of intensive care patients over the age of 18 who received at least 24 hours of inpatient treatment between 2017-2023 in the intensive care unit of the Department of Anesthesiology and Re-animation in Suleyman Demirel University and who used at least one other drug in addition to the active substance Linezolid during this period were used. All these data were evaluated with the Lexi-Interact program. Results: 68(36%) patients included in the study were exposed to polypharmacy for 2-22 days, 69(36.5%) patients for 23-45 days, and 52(27.5%) patients for 46-197 days during their treatment. A total of 655 interactions were identified. Of these, 17(8.99%) type A, 172(91%) type B, 183(96.83%) type C, 184(97.35%) type D, and 99(52.38%) type X interactions were detected. As a result of the examination of potential drug-drug interactions (pDDIs) in terms of dual drug use with Linezolid, it was seen that the most frequent type C interaction could occur with Quetiapine (33;17.20%), type D interaction with Salbutamol (94;49.70%), and type X interactions which are not recommended for use side by side with Linezolid could occur with Metoclopropamide (44;23.30%) and Escitalopram (11;5.80%). Conclusion: Linezolid-treated ICU patients exhibited a high prevalence of potential drug-drug interactions, particularly involving sympathomimetic and serotonergic agents. These findings highlight the importance of routine interaction screening and careful monitoring when linezolid is prescribed in critically ill patients.
